Suscribirse

HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE COMBINED IMMUNODEFICIENCY DISEASE - 04/09/11

Doi : 10.1016/S0889-8561(05)70142-9 
Trudy Small, MD *

Resumen

Severe combined immunodeficiency disease (SCID) refers to a heterogeneous group of rare (1/100,000 live births), lethal, congenital disorders that result in the inability of T cells to respond to mitogens, alloantigens, and specific antigens and B cells to produce specific antibodies.1 Before the early 1990s, patients with this disorder were characterized primarily by the phenotype and function of their circulating lymphocytes, mode of inheritance, and presence or absence of enzyme deficiencies known to be associated with SCID, such as adenosine deaminase. In this original classification, three main types of SCID were described2 and include the following: (1) classical SCID, characterized by T and B lymphopenia, with or without natural killer (NK) cells, and agammaglobulinemia, (2) the more common SCID with B lymphocytes, and (3) SCID secondary to adenosine deaminase (ADA) deficiency, which may present with either of the preceding lymphoid phenotypes.3, 4 Less often, children with SCID present with Omenn's syndrome,5 in which affected infants have scaling erythroderma, leukocytosis, eosinophilia, hepatosplenomegaly, and lymphadenopathy with replacement of nodal architecture by Langerhans and reticulum cells,6 reticular dysgenesis,7 in which SCID is associated with severe neutropenia and often bilateral sensorineural deafness,8 or SCID with short-limbed dwarfism and ectodermal dysplasia.9 Multiple variants of SCID have been described in which patients have nonfunctional T cells that demonstrate capping defects,10 lack CD711 or possess abnormal CD3 subunit expression,12 or have CD8 deficiency with nonfunctional CD4+ cells.13, 14 Despite this phenotypic heterogeneity, the distribution of SCID phenotypes reported in four separate studies performed in Europe and the United States was surprisingly similar.15, 16, 17, 18 Approximately 40% of patients presented as SCID with B cells, 25% as classical SCIDs (BT), 15% with ADA deficiency, 10% as SCIDs with nonfunctional T cells, and 2% to 3% with reticular dysgenesis. Inheritance of these disorders are either autosomal recessive (ADA deficiency,4, 19 short-limbed dwarfism,9 Omenn's syndrome,5 capping defects,10 CD8 deficiency,13, 14 or as either an X-linked or autosomal recessive disorder (classical SCID, SCID with B cells, reticular dysgenesis).14, 20

Although first trimester diagnosis of adenosine deaminase deficiency has been possible for many years by measurement of enzyme activity in cultured amniocytes or chorionic villi samples,21 children with ADA+ SCID, until recently, required fetal blood sampling to ascertain the presence or absence of T cells.22 The elucidation of many of the genetic mutations which give rise to SCID, such as X-linked SCID (IL-2R gamma chain),23, 24, 25 autosomal recessive SCID with B cells (JAK-3),26, 27 classic SCID, Omenn's syndrome28, 29, 30, 31 (recombinase defects (RAG-1, RAG-2), and CD8 deficiency with nonfunctional T-cells (ZAP-70),32, 33, 34 has increased the proportion of infants who can be diagnosed by amniocentesis or chorionic villus sampling (CVS).35, 36 Better prenatal diagnosis, earlier postnatal diagnosis, because of heightened awareness of immunodeficiency disorders resulting from the AIDS epidemic, in conjunction with advances in anti-microbial therapy, have reduced the number of children presenting to bone marrow transplant (BMT) with a life-threatening infection.

Successful correction of SCID by BMT was first reported by Gatti et al using bone marrow derived from an HLA-matched sibling.37 Since that report, over 500 curative transplants for this disorder have been performed,38 the majority using T-cell–depleted haploidentical parental bone marrow. Within the last 5 years, advances in unrelated bone marrow39 and cord blood transplantation40 and successes with in utero stem cell transplants41 have expanded the options available to infants with SCID, particularly those lacking an HLA-matched sibling. In this article, the results and continued controversies of stem cell transplantation for SCID are reviewed.

El texto completo de este artículo está disponible en PDF.

Esquema


 Address reprint requests to Trudy Small, MD, Bone Marrow Transplant Service, Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Room H-1406, New York, NY 10021, e-mail: Small_Trudy_N/mskcc_PED@mskmail.mskcc.org


© 2000  W. B. Saunders Company. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 20 - N° 1

P. 207-220 - février 2000 Regresar al número
Artículo precedente Artículo precedente
  • ATAXIA-TELANGIECTASIA : A Primary Immunodeficiency Revisited
  • José R. Regueiro, Oscar Porras, Martin Lavin, Richard A. Gatti
| Artículo siguiente Artículo siguiente
  • GENE THERAPY FOR T-CELL IMMUNODEFICIENCIES
  • Donald B. Kohn, Kenneth I. Weinberg, Robertson Parkman

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.